The US faces a fiscal tidal wave on the horizon. Reforming Medicare Part D may be one way of escaping it. Government Accountability Office Director David Walker preaches a stern warning.
By David Walker
David Walker is the Comptroller General of the US Government Accountability Office. His remarks were given in a speech at...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.
